These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35438137)

  • 1. Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS).
    Maeda H; Saito N; Igarashi A; Ishida M; Suami K; Yagiuchi A; Kimura Y; Komino M; Arai H; Morikawa T; Motohashi I; Miyazawa R; Moriyama T; Kamura H; Terada M; Kuwamitsu O; Hayakawa T; Sando E; Ohara Y; Teshigahara O; Suzuki M; Morimoto K
    Clin Infect Dis; 2022 Nov; 75(11):1971-1979. PubMed ID: 35438137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of BNT162b2 Vaccine Against Symptomatic SARS-CoV-2 Infection in Children Aged 5-11 Years in Japan During Omicron Variant Predominate Periods.
    Hara M; Ohta Y; Fusazaki N; Hirota Y
    J Epidemiol; 2024 May; 34(5):205-210. PubMed ID: 37460294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
    Maeda H; Saito N; Igarashi A; Ishida M; Terada M; Ito T; Ikeda H; Kamura H; Motohashi I; Kimura Y; Komino M; Arai H; Kuwamitsu O; Akuzawa N; Sando E; Morikawa T; Imura H; Inoue H; Hayakawa T; Teshigahara O; Ohara Y; Suzuki M; Morimoto K
    Expert Rev Vaccines; 2023; 22(1):288-298. PubMed ID: 36883371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
    Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
    Maeda H; Saito N; Igarashi A; Ishida M; Terada M; Masuda S; Osawa R; Hosokawa N; Nakashima K; Kamura H; Imura H; Inoue H; Matsuzaka S; Sugimoto Y; Kuwamitsu O; Motohashi I; Morikawa T; Oda R; Hoshina Y; Matono T; Teshigahara O; Sando E; Asami S; Kudo S; Akizuki N; Muto Y; Hayakawa T; Kishaba T; Ohara Y; Kubo Y; Suzuki M; Morimoto K
    Expert Rev Vaccines; 2024; 23(1):213-225. PubMed ID: 38288980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
    Florentino PTV; Millington T; Cerqueira-Silva T; Robertson C; de Araújo Oliveira V; Júnior JBS; Alves FJO; Penna GO; Vital Katikireddi S; Boaventura VS; Werneck GL; Pearce N; McCowan C; Sullivan C; Agrawal U; Grange Z; Ritchie LD; Simpson CR; Sheikh A; Barreto ML; Rudan I; Barral-Netto M; Paixão ES
    Lancet Infect Dis; 2022 Nov; 22(11):1577-1586. PubMed ID: 35952702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.
    Kerr S; Vasileiou E; Robertson C; Sheikh A
    J Glob Health; 2022 Jul; 12():05025. PubMed ID: 35802764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Tartof SY; Slezak JM; Fischer H; Hong V; Ackerson BK; Ranasinghe ON; Frankland TB; Ogun OA; Zamparo JM; Gray S; Valluri SR; Pan K; Angulo FJ; Jodar L; McLaughlin JM
    Lancet; 2021 Oct; 398(10309):1407-1416. PubMed ID: 34619098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant.
    Eick-Cost AA; Ying S; Wells N
    JAMA Netw Open; 2022 Apr; 5(4):e228071. PubMed ID: 35442453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    Price AM; Olson SM; Newhams MM; Halasa NB; Boom JA; Sahni LC; Pannaraj PS; Irby K; Bline KE; Maddux AB; Nofziger RA; Cameron MA; Walker TC; Schwartz SP; Mack EH; Smallcomb L; Schuster JE; Hobbs CV; Kamidani S; Tarquinio KM; Bradford TT; Levy ER; Chiotos K; Bhumbra SS; Cvijanovich NZ; Heidemann SM; Cullimore ML; Gertz SJ; Coates BM; Staat MA; Zinter MS; Kong M; Chatani BM; Hume JR; Typpo KV; Maamari M; Flori HR; Tenforde MW; Zambrano LD; Campbell AP; Patel MM; Randolph AG;
    N Engl J Med; 2022 May; 386(20):1899-1909. PubMed ID: 35353976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    Andrews N; Tessier E; Stowe J; Gower C; Kirsebom F; Simmons R; Gallagher E; Thelwall S; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown K; Hopkins S; Chand M; Ladhani SN; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Jan; 386(4):340-350. PubMed ID: 35021002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Sukik L; Chemaitelly H; Ayoub HH; Coyle P; Tang P; Yassine HM; Al Thani AA; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abdel-Rahman ME; Abu-Raddad LJ
    Vaccine; 2024 May; 42(14):3307-3320. PubMed ID: 38616439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study.
    Mimura W; Ishiguro C; Terada-Hirashima J; Matsunaga N; Sato S; Kawazoe Y; Maeda M; Murata F; Fukuda H
    J Epidemiol; 2024 Jun; 34(6):278-285. PubMed ID: 37743530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
    Olson SM; Newhams MM; Halasa NB; Price AM; Boom JA; Sahni LC; Pannaraj PS; Irby K; Walker TC; Schwartz SP; Maddux AB; Mack EH; Bradford TT; Schuster JE; Nofziger RA; Cameron MA; Chiotos K; Cullimore ML; Gertz SJ; Levy ER; Kong M; Cvijanovich NZ; Staat MA; Kamidani S; Chatani BM; Bhumbra SS; Bline KE; Gaspers MG; Hobbs CV; Heidemann SM; Maamari M; Flori HR; Hume JR; Zinter MS; Michelson KN; Zambrano LD; Campbell AP; Patel MM; Randolph AG;
    N Engl J Med; 2022 Feb; 386(8):713-723. PubMed ID: 35021004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.